Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 17 of 17 results for carfilzomib

  1. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

    Withdrawn guidance

  2. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA959